PriceTargets.com logo

Regencell Bioscience - RGC Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$16.00 As of 12/4/2025 05:00 PM ET
▲ +2.99 (22.98%)

This chart shows the closing price for RGC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Regencell Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Regencell Bioscience in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $16.00.

This chart shows the closing price for RGC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Regencell Bioscience.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 3 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Regencell Bioscience logo
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Read More

Today's Range

Now: $16.00
Low: $13.14
High: $18.15

50 Day Range

MA: $14.98
Low: $11.11
High: $20.05

52 Week Range

Now: $16.00
Low: $0.09
High: $83.60

Volume

1,120,769 shs

Average Volume

136,223 shs

Market Capitalization

$7.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Regencell Bioscience?

The following Wall Street analysts have issued stock ratings on Regencell Bioscience in the last year: Weiss Ratings.
View the latest analyst ratings for RGC.

What is the current price target for Regencell Bioscience?

0 Wall Street analysts have set twelve-month price targets for Regencell Bioscience in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Regencell Bioscience in the next year.
View the latest price targets for RGC.

What is the current consensus analyst rating for Regencell Bioscience?

Regencell Bioscience currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe RGC will underperform the market and that investors should sell shares of Regencell Bioscience.
View the latest ratings for RGC.

What other companies compete with Regencell Bioscience?

Other companies that are similar to Regencell Bioscience include BioNTech, Genmab A/S, Revolution Medicines, Roivant Sciences and Summit Therapeutics. Learn More about companies similar to Regencell Bioscience.

How do I contact Regencell Bioscience's investor relations team?

Regencell Bioscience's physical mailing address is 11/F FIRST COMMERCIAL BUILDING, 33-35 LEIGHTON ROAD, CAUSEWAY BAY, HONG KONG, K3, 999077. The company's listed phone number is 852 2155 0823 and its investor relations email address is [email protected]. The official website for Regencell Bioscience is regencellbioscience.com. Learn More about contacing Regencell Bioscience investor relations.